Recent Advances in Anticancer Photodynamic Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (30 July 2023) | Viewed by 29941
Special Issue Editor
Interests: photodynamic therapy; cancer treatment; drug delivery system
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a significant disease worldwide and its treatment remains a major challenge. Surgery, radiation therapy, and chemotherapy are commonly selected for cancer treatments. However, the limitations of conventional cancer treatments drive the search for new cancer treatments. Photodynamic therapy (PDT) has emerged as a promising alternative cancer treatment option. A photosensitizer, light, and oxygen are the three main elements of PDT. When the photosensitizer is injected into the cancer patient, it distributes in the patient’s body and selectively accumulates in the tumor. PDT may provide higher therapeutic efficacy against tumors compared with conventional cancer treatments. To improve the anti-tumor efficacy of PDT, there have been various challenges, such as developing novel photosensitizers and/or light devices, a combination of PDT and other conventional cancer treatments (i.e., chemotherapy, radiotherapy, surgery, immunotherapy, and photothermal therapy).
In this Special Issue, we wish to receive original research articles and review articles regarding novel PDT for cancer treatment. In vitro, in vivo, and clinical studies are all welcome to be presented in this issue.
Dr. Ji-Eun Chang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photodynamic therapy
- cancer treatment
- photosensitizer
- light device
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.